Value of 7 Tesla in gliomas

Value of 7 Tesla in gliomas - Value of 7 Tesla in gliomas

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52838

Enrollment

Registered

2019-05-07

Start date

2021-02-15

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gliomas malignant brain tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age > 18 years - Highly suspected or histologically confirmed glioma - Karnofsky performance status >= 70

Exclusion criteria

Exclusion criteria: - Patients with a contra-indication for MRI (see list LUMC in attachment).

Design outcomes

Primary

Measure	Time frame
The following radiological tumor characteristics will be assessed, if possible within the 60 minutes MRI time, using the optimal imaging protocol of the 1.5/3 T MRI (T1WI with and without gadolinium, T2WI, FLAIR, SWI, perfusion(DSC), DWI) and 7 T MRI (possible relevant sequences: 3DT1, 3DT2, TOF, SWI (Duyn), FLAIR, spectroscopy and CEST). We aim to investigate the feasibility of the following measurements: With the 1.5/3 T MRI: - Tumor boundaries - Tumor vascularization - Number and location of microbleeds - Diffusion restriction - Satellite lesions/multifocality of the tumor - Susceptibility artifacts near tissue boundaries - Magnetic field inhomogeneities ) - Tumorprogression compared to the previous MRI - Pattern of contrast enhancing With the 7 T MRI: - Tumor boundaries - Tumor vascularization - Number and location of microbleeds - Satellite lesions/multifocality of the tumor - Susceptibility artifacts near tissue boundaries - Magnetic field inhomogeneities (Signal dropout in certain brain regions) - Metabolite information (spectroscopy: lactate, choline, lipids, myoinositol, NAA)	—

Measure

Time frame

The following radiological tumor characteristics will be assessed, if possible within the 60 minutes MRI time, using the optimal imaging protocol of the 1.5/3 T MRI (T1WI with and without gadolinium, T2WI, FLAIR, SWI, perfusion(DSC), DWI) and 7 T MRI (possible relevant sequences: 3DT1, 3DT2, TOF, SWI (Duyn), FLAIR, spectroscopy and CEST). We aim to investigate the feasibility of the following measurements: With the 1.5/3 T MRI: - Tumor boundaries - Tumor vascularization - Number and location of microbleeds - Diffusion restriction - Satellite lesions/multifocality of the tumor - Susceptibility artifacts near tissue boundaries - Magnetic field inhomogeneities ) - Tumorprogression compared to the previous MRI - Pattern of contrast enhancing With the 7 T MRI: - Tumor boundaries - Tumor vascularization - Number and location of microbleeds - Satellite lesions/multifocality of the tumor - Susceptibility artifacts near tissue boundaries - Magnetic field inhomogeneities (Signal dropout in certain brain regions) - Metabolite information (spectroscopy: lactate, choline, lipids, myoinositol, NAA)

—

Secondary

Measure	Time frame
- Duration of individual scans and the resolution needed - Added value of each sequence in the diagnosis process - Necessary protocol differences between operated and non-operated patients - Robustness of sequences, especially also for providing good quality in challenging regions (near cavities, operation zone, etc.) - Characterization of tumor (pseudo)progression	—

Countries

Netherlands

Outcome results